Resolutions at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolutions follows.
Press releases
Abliva AB Year-End Report January – December 2022
A successful financing enabled the start of the FALCON study with KL1333
Notice of Extraordinary General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 11.00 a.m. on Wednesday 8 March 2023 at ...
Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings
The Nomination Committee of Abliva AB proposes that Dr. Edwin Moses be elected as a new Board member of the Company through a shareholder vote at the EGM on March 8, 2023. Dr. Moses, who has over 30 y ...
Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the granting of a composition of ...
Abliva Appoints Dag Nesse as Vice President of Clinical Operations
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the appointment of Dag Nesse as V ...
Abliva initiates the global FALCON study with lead candidate KL1333
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the start of the company’s global ...
Abliva AB Interim Report January – September 2022
Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases
Abliva to participate in World Mitochondrial Disease Week 2022
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will par ...
Abliva AB Interim Report January – June 2022
SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 146,547,924, as a result of a preferential rights issue announced by the Board of ...
Last day of trading with BTA in Abliva
Abliva AB has carried out a rights issue where the subscription period ended June 27, 2022. The rights issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and t ...